Versant Ventures related stories
All articles and analysis
No Longer Sci-FiMany VCs remain wary of bionics, but others believe they can’t go wrong betting on technologies already been proven to restore vision, hearing and the ability to walk.
- Week in deals, Aug. 2, 2010
Summary of tech companies and other startups in North America that raised venture financing in the past week
- Immune Design Raises $32 Million
Immune Design Corp., a Seattle-based, has raised $32 million in Series B funding. ProQuest Investments led the round, and was joined by return backers Column Group, Versant Ventures and Alta Partners.
- peHUB Wire: Tuesday, July 27, 2010
Random Ramblings
- peHUB Wire: Tuesday, July 27, 2010
Random Ramblings
- VC-Backed IPO Pipeline Springs A Leak
The VC-backed IPO pipeline was drained over the past month, with five VC-backed companies going public and two more withdrawing their offerings. Those companies represented around $1 billion in planned raise, while the month's two new registrants only plan to raise a total of $215 million. There also were two China-based issuers who both filed and priced within the month (HiSoft and AutoNavi). All of this means the current VC-backed IPO pipeline has 39 companies seeking to raise nearly $3.4 billion. That's the lowest dollar expectation since we began keeping track back in January. The full pipeline is after the jump..
- Exit watch, week of July 12, 2010
News briefs about Greenplum, Playdom and other VC-backed companies that were recently acquired
- Investors in eye-related companies focus on exits
”LensX Lasers, bought for more than $361M in cash, the latest eye company to be bought
- Don’t Shed a Tear for Eye Investors
Venture capitalists have put a lot of money over the past couple of years into companies developing treatments for eye disease. Now they’re seeing some ROI. This week, venture backers in LensX Lasers got what looks on paper to be a very nice exit that could turn into a much better one, when Alcon announced that it has entered into a definitive agreement to acquire the company. Alcon will pay US $361.5 million in cash for LenSX, a developer of a laser used in cataract treatment, plus maximum contingent payments of US $382.5 million if it hits agreed-upon milestones. Four-year-old LenSx, which developed what Alcon says developed is first femtosecond laser to receive U.S. Food and Drug Administration clearance for use as a part of cataract surgery, previously raised $32 million in venture funding. The Aliso Viejo, Calif.-based company’s investors include InterWest Partners, SV Life Sciences Advisers and Versant Ventures.